Comparing Intra-arterial and Intravenous rt-PA for Stroke Treatment in Rats
Author Information
Author(s): Crumrine R. Christian, Marder Victor J., Taylor G. McLeod, LaManna Joseph C., Tsipis Constantinos P., Scuderi Philip, Petteway Stephen R Jr, Arora Vikram
Primary Institution: Grifols Therapeutics, Inc.
Hypothesis
Intra-arterial administration of rt-PA causes more intracranial bleeding than intravenous rt-PA in a transient rat middle cerebral artery occlusion model.
Conclusion
Intra-arterial administration of rt-PA results in greater intracranial bleeding and worse functional recovery compared to intravenous administration.
Supporting Evidence
- Greater hemorrhagic transformation occurred with 10 and 30 mg/kg rt-PA administered intra-arterially compared to intravenously.
- The intravenous 10 mg/kg rt-PA dosage induced significantly less bleeding than the 1 or 5 mg/kg intra-arterial groups.
- No significant increase in infarct volume was observed after either treatment.
- Rats treated with 30 mg/kg rt-PA by either route had greater neurological dysfunction compared to all other groups.
Takeaway
Giving a medicine called rt-PA directly into the artery in the brain can cause more bleeding than giving it through a vein, even if the dose is much smaller.
Methodology
Male spontaneously hypertensive rats were treated with either intra-arterial or intravenous rt-PA after 6 hours of middle cerebral artery occlusion, and outcomes were measured 24 hours later.
Potential Biases
Potential bias due to the authors' affiliations with Grifols Therapeutics, Inc.
Limitations
The study had a limited number of rats in some treatment groups, which may affect the generalizability of the results.
Participant Demographics
Adult male spontaneously hypertensive rats weighing 330 - 380 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website